Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.

Monoclonal antibodies (mAbs) are an upcoming group of therapeutic compounds used to treat various types of diseases. Currently more than 100 mAbs are in clinical development. To establish the pharmacokinetic (PK) properties of mAbs many (pre-)clinical studies are executed. Samples of these studies are most often analysed using immunoassays. Although immunoassays are very fast and sensitive, there are also some limitations. Alternative assays using e.g. liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), therefore, are also being developed. This paper reviews methods for the bioanalysis of the therapeutic mAbs that are currently registered, and their application in (pre-) clinical PK studies. We will focus on immunoassays and will make the comparison with other analytical techniques. We conclude that immunoassays are still the analytical technique of first choice for the analysis of mAbs, but that, unfortunately, the provided information in the literature about method performance is scarce.

[1]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[2]  N. Eter,et al.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. , 2008, American journal of ophthalmology.

[3]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[4]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Thariat,et al.  Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Ariagno,et al.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. , 1998, The Pediatric infectious disease journal.

[7]  M. Pescovitz,et al.  Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation , 2003, Clinical transplantation.

[8]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[9]  M. Garovoy,et al.  Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  T. Matsushita,et al.  No changes in infliximab levels in blood stored for preoperative autologous blood donation , 2008, Modern rheumatology.

[11]  T. Vollmer,et al.  An open-label safety and drug interaction study of natalizumab (Antegren™) in combination with interferon-beta (Avonex®) in patients with multiple sclerosis , 2004, Multiple sclerosis.

[12]  M. Narabayashi,et al.  Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. le Pape,et al.  Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. , 2009, Blood.

[14]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[15]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Toutain,et al.  A preclinical pharmacokinetic/pharmacodynamic approach to determine a dose of GnRH, for treatment of ovarian follicular cyst in cattle. , 2004, Journal of veterinary pharmacology and therapeutics.

[17]  J. Kovarik,et al.  Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients , 2001, Clinical transplantation.

[18]  N. Mendenhall,et al.  Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Kovarik,et al.  Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.

[20]  A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy , 2007, Modern rheumatology.

[21]  S. Crawford,et al.  Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. , 2001, The Journal of infectious diseases.

[22]  L. Norton,et al.  Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Taniwaki,et al.  Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Slavin,et al.  Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. , 2009, The Journal of allergy and clinical immunology.

[25]  C. Hudis,et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.

[26]  B. Nashan,et al.  Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. , 2002, Transplantation.

[27]  M. Schreier,et al.  Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.

[28]  I. Nestorov Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.

[29]  P. Lipsky,et al.  Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.

[30]  S. Liao,et al.  Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis , 2009, Journal of clinical pharmacology.

[31]  M. Hidalgo,et al.  Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors , 2006, Clinical Cancer Research.

[32]  S. Meri,et al.  Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma , 2001, Leukemia & lymphoma.

[33]  P. Kwon,et al.  Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti‐CD11a Antibody) Following Long‐Term Subcutaneous Weekly Dosing in Psoriasis Subjects , 2005, Journal of clinical pharmacology.

[34]  S. Pyati,et al.  Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care Unit , 2004, Pediatrics.

[35]  Binodh DeSilva,et al.  Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.

[36]  Y. Sasaki,et al.  Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer , 1999, British Journal of Cancer.

[37]  M. Varughese,et al.  Pharmacokinetics of CAMPATH-1H in BMT patients. , 2001, Cytotherapy.

[38]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[39]  K. Gelmon,et al.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Beer,et al.  VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS , 2006, Retina.

[41]  P. Rutgeerts,et al.  Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[42]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma , 1994 .

[43]  R. Tacey,et al.  Development and validation of ELISA for herceptin detection in human serum. , 2004, Journal of immunological methods.

[44]  P. Klein,et al.  Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.

[45]  J. Kovarik,et al.  A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations1 , 2002, Transplantation.

[46]  J. Kuhlmann,et al.  Pharmacokinetics of alemtuzumab and the relevance in clinical practice , 2008, Leukemia & lymphoma.

[47]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[49]  R. Herbst,et al.  Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. , 2004, Lung cancer.

[50]  F. Vincenti,et al.  Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[51]  R. Busuttil,et al.  Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. , 1990, Transplantation proceedings.

[52]  Yvonne S. Lin,et al.  Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys , 2008, Cancer Chemotherapy and Pharmacology.

[53]  D. Mould,et al.  A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.

[54]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[55]  Y. Ohashi,et al.  Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphoma , 2006, Cancer science.

[56]  R. Ransohoff,et al.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.

[57]  G. Klintmalm,et al.  A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  L. Matis,et al.  Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. , 1996, Molecular immunology.

[59]  A. Joshi,et al.  Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis , 2005, Pharmaceutical Research.

[60]  A. Gottlieb,et al.  Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis , 2003, Journal of cutaneous medicine and surgery.

[61]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[62]  Olivier Heudi,et al.  Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.

[63]  L. Visai,et al.  A New Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) for Alemtuzumab Determination: Development, Validation and Application , 2007, International journal of immunopathology and pharmacology.

[64]  M. Czuczman,et al.  Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  S. Perkins,et al.  A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study , 2007, Clinical Cancer Research.

[66]  Vinod P. Shah,et al.  Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.

[67]  A. Gottlieb,et al.  A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis , 2007, Current medical research and opinion.

[68]  E. Franssen,et al.  Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  M. Koller,et al.  A safety and pharmacokinetic study of intravenous natalizumab in patients with MS , 1999, Neurology.

[70]  J. Pulido,et al.  Pharmacokinetics of intravitreal bevacizumab (Avastin). , 2007, Ophthalmology.

[71]  T. Kishimoto,et al.  Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.

[72]  F. Breedveld,et al.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status , 2008, Clinical Rheumatology.

[73]  J. Kovarik,et al.  A population pharmacokinetic screen to identify demographic‐clinical covariates of basiliximab in liver transplantation , 2001, Clinical pharmacology and therapeutics.

[74]  O. Ramilo,et al.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. , 2008, The Journal of pediatrics.

[75]  Jos H Beijnen,et al.  Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. , 2009, Analytical biochemistry.

[76]  J. W. Findlay,et al.  Some important considerations for validation of ligand-binding assays. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[77]  B. Dijkmans,et al.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[78]  M Taniwaki,et al.  Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  M. Mochizuki,et al.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. , 2004, The Journal of rheumatology.

[80]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[81]  A. Thomas,et al.  Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents , 2007, Journal of pediatric gastroenterology and nutrition.

[82]  H. Lui,et al.  The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. , 2001, Journal of the American Academy of Dermatology.

[83]  D. Mould,et al.  Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. , 1995, Journal of immunological methods.

[84]  R. Kozarek,et al.  Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab , 2007, Inflammatory bowel diseases.

[85]  Helen X. Chen,et al.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  D. Wright,et al.  Environmental toxicology: Factors affecting toxicity , 2002 .

[87]  R. Pounder,et al.  A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease , 2001 .

[88]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[89]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[90]  B. Dijkmans,et al.  Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation , 2007, Annals of the rheumatic diseases.

[91]  D. Combs,et al.  Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial , 2005, Journal of clinical pharmacology.

[92]  G. Paintaud,et al.  Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients , 2008, Therapeutic drug monitoring.

[93]  D. Podoloff,et al.  Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. , 2003, Cancer biotherapy & radiopharmaceuticals.

[94]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[95]  J. Pulido,et al.  SIX-MONTH STABILITY OF BEVACIZUMAB (AVASTIN) BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER WITHDRAWAL INTO A SYRINGE AND REFRIGERATION OR FREEZING , 2006, Retina.

[96]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[97]  H. Paulus,et al.  Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.

[98]  L. V. D. van de Putte,et al.  A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[99]  L. Czer,et al.  Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. , 1995, Clinical transplantation.

[100]  Xinping Fang,et al.  LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. , 2007, Analytical chemistry.

[101]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[102]  P. Vereerstraeten,et al.  OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[103]  K. Gelmon,et al.  Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels , 2005, Pharmaceutical Research.

[104]  A. Gottlieb,et al.  Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. , 2003, Journal of the American Academy of Dermatology.

[105]  J A Parker,et al.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.

[106]  F. Lee,et al.  Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft , 2005, Cancer Chemotherapy and Pharmacology.

[107]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[108]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  M. Grever,et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Baselga,et al.  Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  T. Waldmann,et al.  Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. , 2003, Journal of autoimmunity.

[114]  R. Colvin,et al.  OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. , 1986, Transplantation.

[115]  V. Zagonel,et al.  Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. , 2000, Therapeutic drug monitoring.

[116]  P. Szurman,et al.  Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. , 2008, Ophthalmology.

[117]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[118]  J. Kovarik,et al.  Disposition and immunodynamics of basiliximab in liver allograft recipients , 1998, Clinical pharmacology and therapeutics.

[119]  J. Roberts,et al.  Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. , 2000, Transplantation.

[120]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[121]  L. Gordon,et al.  Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis , 2006, Leukemia & lymphoma.

[122]  M. Pescovitz,et al.  Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients , 2008, Pediatric transplantation.

[123]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[124]  M. Dietlein,et al.  Imaging of central nervous system lymphomas with iodine‐123 labeled rituximab , 2005, European journal of haematology.

[125]  Darrell Ricke,et al.  Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.

[126]  J. Kovarik,et al.  Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. , 1999, Transplantation.

[127]  T. Vollmer,et al.  A phase I trial of an interleukin‐12/23 monoclonal antibody in relapsing multiple sclerosis , 2006, Current medical research and opinion.

[128]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  Ivan Nestorov,et al.  Clinical pharmacokinetics of tumor necrosis factor antagonists. , 2005, The Journal of rheumatology. Supplement.

[130]  M. Albitar,et al.  Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab. , 2007, Methods in molecular biology.

[131]  T. Schnitzer,et al.  CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. , 1996, British journal of rheumatology.

[132]  J. Kovarik,et al.  A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[133]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  A. Gottlieb,et al.  Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis , 2005, Journal of clinical pharmacology.

[135]  M. Tomonaga,et al.  Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody , 2001, International journal of hematology.

[136]  Suzanne F. Jones,et al.  A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing , 2007, Clinical Cancer Research.

[137]  J. Kovarik,et al.  Pharmacokinetics and immunodynamics of chimeric IL‐2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[138]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[139]  Krys J. Miller,et al.  Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.

[140]  B. Mounho,et al.  Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics , 2005, International journal of toxicology.

[141]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[142]  O. Ramilo,et al.  Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection , 2004, The Pediatric infectious disease journal.

[143]  T. Waldmann,et al.  Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. , 2006, Leukemia research.

[144]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Y. Tsukamoto,et al.  A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. , 2007, British journal of clinical pharmacology.

[146]  E. Raymond,et al.  Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. , 2005, European journal of cancer.

[147]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[148]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[149]  Mahboob Rahman,et al.  Double-blinded infliximab dose escalation in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[150]  B. Meibohm,et al.  Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck , 2008, Journal of clinical pharmacology.

[151]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[152]  W. Wilson,et al.  The pharmacokinetics of rituximab following an intravitreal injection. , 2006, Experimental eye research.

[153]  K. Bartz-Schmidt,et al.  Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.

[154]  H. Kantarjian,et al.  Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. , 2004, Leukemia research.

[155]  A. Gottlieb,et al.  Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. , 2002, Archives of dermatology.

[156]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[157]  Honghui Zhou,et al.  Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis , 2008, Journal of clinical pharmacology.

[158]  S. Richards,et al.  Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[159]  L J Kricka,et al.  Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.

[160]  K. Aldape,et al.  Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.

[161]  O. Ramilo,et al.  Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia , 1998 .

[162]  E. Kimby,et al.  Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. , 2004, Blood.

[163]  R. Pounder,et al.  A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrin , 2002, Alimentary pharmacology & therapeutics.

[164]  T. Vollmer,et al.  Randomized multicenter trial of natalizumab in acute MS relapses , 2004, Neurology.

[165]  R. Figlin,et al.  Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[166]  C. Wagner,et al.  Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.

[167]  J. Jett,et al.  A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients , 2004, Supportive Care in Cancer.

[168]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[169]  E. Ezan,et al.  Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. , 2008, Analytical chemistry.

[170]  G. Martinelli,et al.  High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment , 2007, Journal of Nuclear Medicine.

[171]  P. Mclaughlin,et al.  Rituximab in indolent lymphoma: the single-agent pivotal trial. , 1999, Seminars in oncology.

[172]  C. Ustun,et al.  Treatment of a patient with end‐stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis , 2002, American journal of hematology.

[173]  L. Arcaini,et al.  Pharmacokinetic Behavior of Rituximab: A Study of Different Schedules of Administration for Heterogeneous Clinical Settings , 2005, Therapeutic drug monitoring.

[174]  A. Kennedy,et al.  Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. , 2004, Journal of immunological methods.

[175]  M. Maurel,et al.  Evaluation of a peptide ELISA for the detection of rituximab in serum. , 2007, Journal of immunological methods.

[176]  Klemens Scheidhauer,et al.  Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[177]  P. Bonate,et al.  Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. , 2007, British journal of clinical pharmacology.

[178]  M. Maia,et al.  Subretinal bevacizumab detection after intravitreous injection in rabbits. , 2008, Investigative ophthalmology & visual science.

[179]  M. Mascelli,et al.  Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development , 2007, Journal of clinical pharmacology.

[180]  P. Rosenfeld,et al.  Promising new treatments for neovascular age-related macular degeneration , 2006, Expert opinion on investigational drugs.

[181]  G. Hale,et al.  Pharmacokinetics of CAMPATH-1H: assay development and validation. , 2002, Journal of immunological methods.

[182]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[183]  C. Piggee Therapeutic antibodies coming through the pipeline. , 2008, Analytical chemistry.

[184]  T. Illidge,et al.  A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. , 2004, Blood.

[185]  Binodh DeSilva,et al.  Key elements of bioanalytical method validation for macromolecules , 2007, The AAPS Journal.

[186]  J. Berlin,et al.  Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.

[187]  R H Wheeler,et al.  Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  A. Gottlieb,et al.  A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. , 2004, The Journal of investigative dermatology.

[189]  Lars Bäckman,et al.  INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .

[190]  D. Abendroth,et al.  Screening for basiliximab exposure–response relationships in renal allotransplantation , 1999, Clinical transplantation.

[191]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  J. Kovarik,et al.  Pharmacokinetics and Immunodynamics of Basiliximab in Pediatric Renal Transplant Recipients on Mycophenolate Mofetil Comedication , 2008, Transplantation.

[193]  J. Fridlyand,et al.  Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  D. Podoloff,et al.  Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[195]  S. Ogawa,et al.  Pharmacokinetics of alemtuzumab after haploidentical HLA‐mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52‐positive malignancies , 2006, American journal of hematology.